NextCell Pharma AB (STO:NXTCL)

Market Cap	130.55M +68.5%
Revenue (ttm)	9.83M +4.1%
Net Income	-38.79M
EPS	n/a
Shares Out	111.39M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,255
Average Volume	942,264
Open	1.170
Previous Close	1.172
Day's Range	1.130 - 1.170
52-Week Range	0.630 - 1.784
Beta	0.65
RSI	49.13
Earnings Date	May 28, 2026

About NextCell Pharma AB

NextCell Pharma AB, a biopharmaceutical company, engages in the research and development of novel stem cell therapies in Sweden. The company develops ProTrans, a drug candidate comprising stem cells primarily for treating autoimmune and inflammatory diseases. It also provides Cellaviva, a stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue. NextCell Pharma AB was incorporated in 2014 and is based in Huddinge, Sweden.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 24
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: NXTCL

Financial Performance

In 2025, NextCell Pharma AB's revenue was 9.83 million, a decrease of -11.13% compared to the previous year's 11.06 million. Losses were -38.79 million, 10.4% more than in 2025.